Introduction: Collection by apheresis is often overlooked in the cell therapy manufacturing process.
With the decommissioning of the Cobe Spectra, there is a need to evaluate whether
replacement apheresis platforms will have any negative impacts. This pilot study compared
the Cobe Spectra with the Spectra Optia Mononuclear Cell (MNC) and the more recent
cMNC programmes.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
